Peter J. Schmid

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

Safety of withdrawal of pharmacological treatment after recovery from HER2 therapy-related cardiac dysfunction: the HER-SAFE trial.

Journal: European heart journal

Published: July 06, 2026

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 26, 2026

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 24, 2026

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.

Journal: ESMO open

Published: January 16, 2026

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N = 7914).

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 10, 2025

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 13, 2025

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Prediction of survival after de-escalated neoadjuvant therapy in HER2-positive early breast cancer: a pooled analysis of three WSG trials.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 30, 2025

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292).

Journal: ESMO open

Published: April 07, 2025

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial.

Journal: ESMO open

Published: March 10, 2025

Redefining clinical trial strategic design to support drug approval in medical oncology.

Redefining clinical trial strategic design to support drug approval in medical oncology.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 27, 2025

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374).

Journal: ESMO open

Published: December 18, 2024

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer.

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer.

Journal: ESMO open

Published: April 11, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026